Plain-English translation of NCT06830850 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called HRS-5041 in men with metastatic castration-resistant prostate cancer—a form of advanced prostate cancer that no longer responds to standard hormone treatments. Researchers want to understand how safe the medication is, how well the body tolerates it, and whether it helps slow or stop the cancer's growth. You would take the medication twice daily at a specific dose.
Men with castration-resistant prostate cancer have limited treatment options once hormone therapy stops working. This trial is exploring whether this medication can offer a new path forward for patients who need additional treatment choices.
You would take the medication by mouth twice each day at a dose of 240 mg. The trial involves multiple visits to the research center where doctors will check your health, run blood tests, and monitor how you're responding to the medication. You cannot receive any other cancer treatments during the study. The trial is enrolling about 25 participants across multiple medical centers.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Australia